pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea

Area of Science:

• Microbiology
• Genetics
• Drug Resistance

Background:

• Pyrazinamide (PZA) is a crucial first-line tuberculosis treatment.
• PZA exhibits antimycobacterial activity against semidormant bacteria, particularly at low pH.
• Understanding PZA resistance mechanisms is vital for effective tuberculosis therapy.

Purpose of the Study:

• To investigate the correlation between pyrazinamide (PZA) resistance and pyrazinamidase (PZase) activity.
• To identify and characterize pncA gene mutations associated with PZA resistance in Mycobacterium tuberculosis.
• To contribute to a global understanding of PZA resistance by expanding the profile of pncA mutations.

Main Methods:

• Phenotypic testing of Mycobacterium tuberculosis strains for PZA susceptibility and PZase activity.
• Genotypic analysis of the pncA gene for mutations in PZA-resistant and susceptible strains.
• Restriction Fragment Length Polymorphism (RFLP) analysis to assess genotypic diversity.

Main Results:

• Six strains were susceptible to PZA, showed PZase activity, and lacked pncA mutations.
• Twenty-one strains exhibited PZA resistance, lacked PZase activity, and possessed pncA mutations (15 point mutations, 5 insertions, 2 deletions).
• A specific adenine to guanine point mutation in the -11 upstream region was the most frequent pncA mutation observed.

Conclusions:

• The study elucidates the molecular basis of PZA resistance, primarily involving pncA gene mutations.
• The adenine to guanine point mutation in the -11 upstream region is identified as a common mechanism of PZA resistance.
• Interpretation of pncA mutation data is crucial for epidemiological studies of tuberculosis.